Hepatology

Diabetes was associated with an increased risk of liver transplant or death and with liver-specific events in patients with PBC.

Zhang explains the safety of different FDA-approved alcohol use disorder drugs in patients with alcohol-associated liver disease.

Liver transplant waitlisting after a weekend was associated with higher 1-year post-transplant mortality compared with patients listed on a weekday.

Teckman explains the value of a new predictive algorithm model for determining future risk of portal hypertension, cirrhosis, and liver transplant in AATD.

GLP-1RA use was associated with a reduced risk of adverse liver outcomes in patients with alcohol-associated liver disease and type 2 diabetes.

Compared with non-Hispanic White patients, racial/ethnic minority patients were more likely to be removed from the waitlist and not receive a transplant.

High adherence to the Mediterranean diet was linked to a lower risk of liver-related outcomes as measured by the Liver Risk score.

Patients with PBC and moderate/severe pruritus face a greater health-related quality of life burden and impaired activity than those with no/mild itch.

Kowdley explains how treatment with elafibranor (Iqirvo) improves transplant-free survival based on changes in GLOBE and UK-PBC prognostic scores.

Kim explains how poor sleep is linked to negative impacts on mental health, physical health, and frailty after liver transplantation.

Treatment with elafibranor (Iqirvo) improved prognostic GLOBE and UK-PBC scores as early as week 4 in the phase 3 ELATIVE trial.

Cohen explains patient perspectives about how healthcare providers can help address the lack of diversity in chronic HBV clinical trials.

Patients with autoimmune hepatitis who are deficient in vitamin D had worse outcomes than patients with normal vitamin D levels.

Stine reviews findings from a posthoc analysis of the NASHFit trial suggesting the impact of exercise on MASH resolution, even without weight loss.

Zoi Papalamprakopoulou, MD, explains telehealth’s potential to aid HCV treatment in high-risk populations and how patients perceive this care modality.

Zhang describes how a novel multidisciplinary care clinic has helped reduce relapse after transplant in patients with alcohol-associated liver disease.

New phase 2b data suggest a combination of VTP-300 and low-dose nivolumab can stimulate immune response and induce HBV functional cure.

Findings from a 2.5-year interim analysis from the ongoing phase 3 ASSURE study highlight seladelpar’s sustained efficacy and long-term safety for PBC.

In areas where HBV immune globulin is not available, maternal TDF therapy at week 16 and infant HBV vaccination can prevent mother-to-child transmission.

A study presented at NASPGHAN 2024 reveals rising incidence rates and improved survival outcomes of Biliary Atresia in the US.

The risk score uses routine clinical data to assess hepatocellular carcinoma risk in patients without viral hepatitis or hepatic decompensation.

The CRL is consistent with the outcome of a September Gastrointestinal Drugs Advisory Committee meeting.

Alkhouri explains the first real-world data on the use of resmetirom (Rezdiffra) in patients with MASH and how they compare to clinical trial findings.

Phase 1b data support proof-of-principle for EBX-102 across microbiome and clinical assessments as well as inflammatory biomarkers for cirrhosis.

Research presented at NASPGHAN 2024 found most children with chronic hepatitis C had neurodevelopmental disorders, highlighting the need for proactive care.